Emerging roles of 3D-culture systems in tackling tumor drug resistance

Abstract

Drug resistance that affects patients universally is a major challenge in cancer therapy. The development of drug resistance in cancer cells is a multifactor event, and its process involves numerous mechanisms that allow these cells to evade the effect of treatments. As a result, the need to understand the molecular mechanisms underlying cancer drug sensitivity is imperative. Traditional 2D cell culture systems have been utilized to study drug resistance, but they often fail to mimic the 3D milieu and the architecture of real tissues and cell-cell interactions. As a result of this, 3D cell culture systems are now considered a comprehensive model to study drug resistance in vitro. Cancer cells exhibit an in vivo behavior when grown in a three-dimensional environment and react to therapy more physiologically. In this review, we discuss the relevance of main 3D culture systems in the study of potential approaches to overcome drug resistance and in the identification of personalized drug targets with the aim of developing patient-specific treatment strategies that can be put in place when resistance emerges.

Keywords

Drug resistance / 3D culture system / extracellular matrix / tumor microenvironment / personalized medicine

References

[1] Gottesman MM.Mechanisms of cancer drug resistance.Annu Rev Med2002;53:615-27

[2] Holohan C,Longley DB.Cancer drug resistance: an evolving paradigm.Nat Rev Cancer2013;13:714-26

[3] Wang X,Chen X.Drug resistance and combating drug resistance in cancer.Cancer Drug Resist2019;2:141-60 PMCID:PMC8315569

[4] Lippert TH,Volm M.Intrinsic and acquired drug resistance in malignant tumors. The main reason for therapeutic failure.Arzneimittelforschung2008;58:261-4

[5] Kelderman S,Haanen JBAG.Acquired and intrinsic resistance in cancer immunotherapy.Mol Oncol2014;8:1132-9 PMCID:PMC5528612

[6] Kaiser J.When less is more.Science2017;355:1144-6

[7] Barretina J,Stransky N.The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity.Nature2012;483:603-7

[8] Basu A,Cheah JH.An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules.Cell2013;154:1151-61 PMCID:PMC3954635

[9] Iorio F,Vis DJ.A landscape of pharmacogenomic interactions in cancer.Cell2016;166:740-54

[10] Ghandi M,Jané-Valbuena J.Next-generation characterization of the cancer cell line encyclopedia.Nature2019;569:503-8

[11] Michaelis M,Cinatl J.Drug-adapted cancer cell lines as preclinical models of acquired resistance.Cancer Drug Resist2019;2:447-56 PMCID:PMC8992517

[12] Rothenburger T,Schreiber Y.Differences between intrinsic and acquired nucleoside analogue resistance in acute myeloid leukaemia cells.J Exp Clin Cancer Res2021;40:317 PMCID:PMC8507139

[13] Wang W,Ohba S.3D spheroid culture system on micropatterned substrates for improved differentiation efficiency of multipotent mesenchymal stem cells.Biomaterials2009;30:2705-15

[14] Hirschhaeuser F,Dittfeld C,Mueller-Klieser W.Multicellular tumor spheroids: an underestimated tool is catching up again.J Biotechnol2010;148:3-15

[15] Lee J,Kotov NA.Three-dimensional cell culture matrices: state of the art.Tissue Eng Part B Rev2008;14:61-86

[16] Elsdale T.Collagen substrata for studies on cell behavior.J Cell Biol1972;54:626-37 PMCID:PMC2200288

[17] Kim JB.Three-dimensional tissue culture models in cancer biology.Semin Cancer Biol2005;15:365-77

[18] Fatehullah A,Barker N.Organoids as an in vitro model of human development and disease.Nat Cell Biol2016;18:246-54

[19] Jensen C.Is it time to start transitioning from 2D to 3D cell culture?.Front Mol Biosci2020;7:33 PMCID:PMC7067892

[20] Takebe T,Radisic M.Synergistic engineering: organoids meet organs-on-a-chip.Cell Stem Cell2017;21:297-300

[21] Ravi M,Kaviya SR,Solomon FDP.3D cell culture systems: advantages and applications.J Cell Physiol2015;230:16-26

[22] Antoni D,Josset E.Three-dimensional cell culture: a breakthrough in vivo.Int J Mol Sci2015;16:5517-27 PMCID:PMC4394490

[23] Huh D,Mammoto A,Hsin HY.Reconstituting organ-level lung functions on a chip.Science2010;328:1662-8 PMCID:PMC8335790

[24] Sambale F,Stahl F.Three dimensional spheroid cell culture for nanoparticle safety testing.J Biotechnol2015;205:120-9

[25] Stoker AW,Martins-Green M.Designer microenvironments for the analysis of cell and tissue function.Curr Opin Cell Biol1990;2:864-74

[26] Fennema E,Rouwkema J,de Boer J.Spheroid culture as a tool for creating 3D complex tissues.Trends Biotechnol2013;31:108-15

[27] Song HHG,Gerecht S.Hydrogels to model 3D in vitro microenvironment of tumor vascularization.Adv Drug Deliv Rev2014;79-80:19-29 PMCID:PMC4258430

[28] Friedl P.Collective cell migration in morphogenesis, regeneration and cancer.Nat Rev Mol Cell Biol2009;10:445-57

[29] Discher DE,Wang YL.Tissue cells feel and respond to the stiffness of their substrate.Science2005;310:1139-43

[30] De Pieri A, Rochev Y, Zeugolis DI. Scaffold-free cell-based tissue engineering therapies: advances, shortfalls and forecast.NPJ Regen Med2021;6:18 PMCID:PMC8007731

[31] Han L,Yu S.The genomic landscape and clinical relevance of A-to-I RNA editing in human cancers.Cancer Cell2015;28:515-28 PMCID:PMC4605878

[32] Langhans SA.Three-dimensional in vitro cell culture models in drug discovery and drug repositioning.Front Pharmacol2018;9:6 PMCID:PMC5787088

[33] Orso F,Dettori D.Role of miRNAs in tumor and endothelial cell interactions during tumor progression.Semin Cancer Biol2020;60:214-24

[34] Rizzolio S,Corso S.The importance of being CAFs (in cancer resistance to targeted therapies).J Exp Clin Cancer Res2022;41:319 PMCID:PMC9632140

[35] Kaur S,Rawal P,Vasudevan A.Non-matrigel scaffolds for organoid cultures.Cancer Lett2021;504:58-66

[36] Bock N,Hipwood L.GelMA, click-chemistry gelatin and bioprinted polyethylene glycol-based hydrogels as 3D ex vivo drug testing platforms for patient-derived breast cancer organoids.Pharmaceutics2023;15:261 PMCID:PMC9867511

[37] Elisseeff J.Hydrogels: structure starts to gel.Nat Mater2008;7:271-3

[38] Murphy SV.3D bioprinting of tissues and organs.Nat Biotechnol2014;32:773-85

[39] Sztankovics D,Petővári G.3D bioprinting and the revolution in experimental cancer model systems - A review of developing new models and experiences with in vitro 3D bioprinted breast cancer tissue-mimetic structures.Pathol Oncol Res2023;29:1610996

[40] Silvestri VL,Linville RM,Searson PC.A tissue-engineered 3D microvessel model reveals the dynamics of mosaic vessel formation in breast cancer.Cancer Res2020;80:4288-301 PMCID:PMC7541732

[41] Groll J,Cho DW.A definition of bioinks and their distinction from biomaterial inks.Biofabrication2018;11:013001

[42] Nunes AS,Costa EC,Correia IJ.3D tumor spheroids as in vitro models to mimic in vivo human solid tumors resistance to therapeutic drugs.Biotechnol Bioeng2019;116:206-26

[43] Costa EC,de Melo-Diogo D,Carvalho MP.3D tumor spheroids: an overview on the tools and techniques used for their analysis.Biotechnol Adv2016;34:1427-41

[44] Däster S,Calabrese D.Induction of hypoxia and necrosis in multicellular tumor spheroids is associated with resistance to chemotherapy treatment.Oncotarget2017;8:1725-36 PMCID:PMC5352092

[45] Nath S.Three-dimensional culture systems in cancer research: focus on tumor spheroid model.Pharmacol Ther2016;163:94-108 PMCID:PMC4961208

[46] Lee KH.Recent advances in multicellular tumor spheroid generation for drug screening.Biosensors2021;11:445 PMCID:PMC8615712

[47] Colombo E.Multicellular 3D models to study tumour-stroma interactions.Int J Mol Sci2021;22:1633 PMCID:PMC7915117

[48] Firuzi O,El Hassouni B.Role of c-MET inhibitors in overcoming drug resistance in spheroid models of primary human pancreatic cancer and stellate cells.Cancers2019;11:638 PMCID:PMC6562408

[49] Drost J.Organoids in cancer research.Nat Rev Cancer2018;18:407-18

[50] Qu J,Liu L,Chen L.Tumor organoids: synergistic applications, current challenges, and future prospects in cancer therapy.Cancer Commun2021;41:1331-53 PMCID:PMC8696219

[51] Ooft SN,Dijkstra KK.Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients.Sci Transl Med2019;11:eaay2574

[52] Öhlund D,Biffi G.Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer.J Exp Med2017;214:579-96 PMCID:PMC5339682

[53] Wen J,Cheng Q.Applications of organoid technology to brain tumors.CNS Neurosci Ther2023;29:2725-43 PMCID:PMC10493676

[54] Bhatia SN.Microfluidic organs-on-chips.Nat Biotechnol2014;32:760-72

[55] Vinci M,Boxall F.Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation.BMC Biol2012;10:29 PMCID:PMC3349530

[56] Wakefield L,Tanner K.Preclinical models for drug discovery for metastatic disease.Cell2023;186:1792-813

[57] Coppo R,Iida K.Distinct but interchangeable subpopulations of colorectal cancer cells with different growth fates and drug sensitivity.iScience2023;26:105962 PMCID:PMC9883198

[58] Hsu PL,Tang YA.Targeting BRD3 eradicates nuclear TYRO3-induced colorectal cancer metastasis.Sci Adv2023;9:eade3422

[59] van de Haar J,Ooft SN.Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer.Nat Med2023;29:605-14

[60] Sui Q,Chen C.Inflammation promotes resistance to immune checkpoint inhibitors in high microsatellite instability colorectal cancer.Nat Commun2022;13:7316

[61] Küçükköse E,Villaudy J.Modeling resistance of colorectal peritoneal metastases to immune checkpoint blockade in humanized mice.J Immunother Cancer2022;10:e005345 PMCID:PMC9772695

[62] Sun Y,Anderson S.Targeting TBK1 to overcome resistance to cancer immunotherapy.Nature2023;615:158-67

[63] Wong TL,Lu S.ADAR1-mediated RNA editing of SCD1 drives drug resistance and self-renewal in gastric cancer.Nat Commun2023;14:2861 PMCID:PMC10199093

[64] Yoon BK,Oh TG.PHGDH preserves one-carbon cycle to confer metabolic plasticity in chemoresistant gastric cancer during nutrient stress.Proc Natl Acad Sci U S A2023;120:e2217826120 PMCID:PMC10214193

[65] Zhou T,Hou X.Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis.J Exp Clin Cancer Res2023;42:111 PMCID:PMC10157938

[66] Goodwin CM,Klomp JE.Combination therapies with CDK4/6 inhibitors to treat KRAS-mutant pancreatic cancer.Cancer Res2023;83:141-57

[67] Hennig A,Klimova A.Detecting drug resistance in pancreatic cancer organoids guides optimized chemotherapy treatment.J Pathol2022;257:607-19

[68] Schuth S,Krieger TG.Patient-specific modeling of stroma-mediated chemoresistance of pancreatic cancer using a three-dimensional organoid-fibroblast co-culture system.J Exp Clin Cancer Res2022;41:312 PMCID:PMC9588250

[69] Li L,Zhang Y,Mao HQ.A combination therapy of bortezomib, CXCR4 inhibitor, and checkpoint inhibitor is effective in cholangiocarcinoma in vivo.iScience2023;26:106095

[70] Su L,Huang C.Targeting src reactivates pyroptosis to reverse chemoresistance in lung and pancreatic cancer models.Sci Transl Med2023;15:eabl7895

[71] Heid J,Jakob Y.3D cell culture alters signal transduction and drug response in head and neck squamous cell carcinoma.Oncol Lett2022;23:177

[72] Fabro F,de Graaf EL.Novel kinome profiling technology reveals drug treatment is patient and 2D/3D model dependent in glioblastoma.Front Oncol2022;12:1012236 PMCID:PMC9670801

[73] Jia W,Zhao M.Potential mechanisms underlying the promoting effects of 3D collagen scaffold culture on stemness and drug resistance of glioma cells.Biochim Biophys Acta Mol Basis Dis2022;1868:166522

[74] Chaicharoenaudomrung N,Promjantuek W.Transcriptomic profiling of 3D glioblastoma tumoroids for the identification of mechanisms involved in anticancer drug resistance.In Vivo2020;34:199-211 PMCID:PMC6984103

[75] Liverani C,Spadazzi C.Lineage-specific mechanisms and drivers of breast cancer chemoresistance revealed by 3D biomimetic culture.Mol Oncol2022;16:921-39 PMCID:PMC8847989

[76] Liu Y,AiErken N.Combining organoid models with next-generation sequencing to reveal tumor heterogeneity and predict therapeutic response in breast cancer.J Oncol2022;2022:9390912 PMCID:PMC9423951

[77] Ng ASN,Mak VCY.AKTIP loss is enriched in ERα-positive breast cancer for tumorigenesis and confers endocrine resistance.Cell Rep2022;41:111821 PMCID:PMC9837615

[78] Anderle N,Gierke B.A platform of patient-derived microtumors identifies individual treatment responses and therapeutic vulnerabilities in ovarian cancer.Cancers2022;14:2895 PMCID:PMC9220902

[79] Senkowski W,Falco MM.A platform for efficient establishment and drug-response profiling of high-grade serous ovarian cancer organoids.Dev Cell2023;58:1106-21.e7 PMCID:PMC10281085

[80] Peterziel H,ElHarouni D.Drug sensitivity profiling of 3D tumor tissue cultures in the pediatric precision oncology program INFORM.NPJ Precis Oncol2022;6:94 PMCID:PMC9794727

[81] Lee DW,Kim SY.A novel 3D pillar/well array platform using patient-derived head and neck tumor to predict the individual radioresponse.Transl Oncol2022;24:101483 PMCID:PMC9294182

[82] Millen R,Koomen M.Patient-derived head and neck cancer organoids allow treatment stratification and serve as a tool for biomarker validation and identification.Med2023;4:290-310.e12

[83] Jensen LH,Lindebjerg J.Precision medicine applied to metastatic colorectal cancer using tumor-derived organoids and in-vitro sensitivity testing: a phase 2, single-center, open-label, and non-comparative study.J Exp Clin Cancer Res2023;42:115 PMCID:PMC10161587

[84] Martini G,Napolitano S.Establishment of patient-derived tumor organoids to functionally inform treatment decisions in metastatic colorectal cancer.ESMO Open2023;8:101198 PMCID:PMC10265597

[85] Papaccio F,Gimeno-Valiente F."Proteotranscriptomic analysis of advanced colorectal cancer patient derived organoids for drug sensitivity prediction".J Exp Clin Cancer Res2023;42:8 PMCID:PMC9817273

[86] Cromwell EF,Nikolov E.Multifunctional profiling of triple-negative breast cancer patient-derived tumoroids for disease modeling.SLAS Discov2022;27:191-200

[87] Shu D,Li K.Organoids from patient biopsy samples can predict the response of BC patients to neoadjuvant chemotherapy.Ann Med2022;54:2581-97

[88] Wang HM,Peng KC.Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: a real-world study.Cell Rep Med2023;4:100911 PMCID:PMC9975107

[89] Mazzocchi A,Soker S.Pleural effusion aspirate for use in 3D lung cancer modeling and chemotherapy screening.Methods Mol Biol2022;2394:471-83

[90] Brown JMC,Ormonde C.A high-density 3-dimensional culture model of human glioblastoma for rapid screening of therapeutic resistance.Biochem Pharmacol2023;208:115410

[91] Morelli M,Barachini S.Metabolic-imaging of human glioblastoma live tumors: a new precision-medicine approach to predict tumor treatment response early.Front Oncol2022;12:969812 PMCID:PMC9483168

[92] Demyan L,Plenker D.Pancreatic cancer patient-derived organoids can predict response to neoadjuvant chemotherapy.Ann Surg2022;276:450-62 PMCID:PMC10202108

[93] Breslin S.Three-dimensional cell culture: the missing link in drug discovery.Drug Discov Today2013;18:240-9

[94] Mazzocchi A,Skardal A.3D bioprinting for high-throughput screening: drug screening, disease modeling, and precision medicine applications.Appl Phys Rev2019;6:011302 PMCID:PMC7968875